Sedana Medical Research Grant 2020 open for applications
Sedana Medical AB (publ) today announced the opening for researchers to apply for Sedana Medical Research Grant 2020. The grant creates a unique opportunity for the scientific community to increase knowledge of sedation therapies of critically ill patients.
Sedana Medical´s mission is to improve patient outcomes through medical innovation. Sedana Medical Research Grant was established in 2019 to stimulate and support international research and increase awareness and knowledge in sedation of critically ill, mechanically ventilated Intensive Care Unit (ICU) patients.
“By supporting sedation research of critically ill ICU patients, our hope is that Sedana Medical Research Grant will be a vital contributor in expanding knowledge in this important field”, said Peter Sackey, Chief Medical Officer at Sedana Medical.
Every year, Sedana Medical grants one to three individual academic researchers between €10 000 and €30 000 per year, for up to two years, through Sedana Medical Research Grant. The grant for 2020/2021 will prioritize research targeting effects and outcome of isoflurane in mechanically ventilated patients, but other sedation-related research may also receive funding.
In 2019, three research projects in Italy, France and Switzerland were selected for funding. Each of these will contribute to forward the science and expand knowledge within ICU sedation in its own way.
Granted applications for 2020/2021 will be presented on Sedana Medical´s homepage in September 2020. For more information on the grant and application procedure please visit: www.sedanamedical.com
For additional information, please contact:
Peter Sackey, CMO, Sedana Medical AB
Mobile: +46 70 771 03 64
E-mail: peter.sackey@sedanamedical.com
Sedana Medical is listed on Nasdaq First North Growth Market in Stockholm.
The company's Certified Adviser is Erik Penser Bank, +46 8 463 83 00, certifiedadviser@penser.se.
About Sedana Medical
Sedana Medical AB (publ) has developed and sells the medical device AnaConDa, for the administration of volatile anaesthetics to mechanically ventilated patients. A major clinical registration study is currently ongoing to obtain market approval in Europe for inhalation sedation in intensive care units with the pharmaceutical IsoConDa® (isoflurane).
Sedana Medical has direct sales in Benelux, France, Nordics, Germany, Spain and Great Britain as well as external distributors in the rest of Europe, Australia, Japan, Canada, Mexico and South Korea. The company headquarters are based in Stockholm, Sweden with R&D operations in Ireland.